Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cougar reports $87 million private placement
The closing of the offering is subject to certain conditions, and is expected to occur on December 20, 2007. Leerink Swann served as lead placement agent for the
The closing of the offering is subject to certain conditions, and is expected to occur on December 20, 2007. Leerink Swann served as lead placement agent for the
The institution’s principal investigator is Albert Cheung, department of anesthesiology, Hospital of the University of Pennsylvania. Ischemic spastic paraplegia is a painful form of extreme spasticity and rigidity
Orphan Europe employs about 120 personnel, and has subsidiaries in nine European countries and in the United Arab Emirates as well as representative offices in seven countries. Recordati’s
Stimuvax is an investigational therapeutic cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a protein antigen widely expressed on common cancers. Merck
This transaction follows PDL’s earlier announced decision to actively pursue the sale of its key assets and is expected to close in the first quarter of 2008. Following
The company said that the new indication allows Thyrogen to be used in conjunction with radioiodine for the most common approach to treating thyroid cancer. This includes surgical
Atripla has been approved in the European Union for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults with virologic suppression to HIV-1 RNA levels < 50copies/ml
At the special meeting of securityholders, the transaction was approved by over 99% of the votes cast by shareholders and by over 99% of the votes cast by
NOV-002 is in pivotal Phase III trial for non-small cell lung cancer under a special protocol assessment and fast track. Lee’s Pharmaceutical, which is 30% owned by Sigma-Tau
In 2006, Biopartners initiated a comparative bioavailability/bioequivalence study in volunteers to assess Valtropin delivered by the Medical House’s GH1. The Medical House has never been able to supply